NZ584037A - Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same - Google Patents

Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same

Info

Publication number
NZ584037A
NZ584037A NZ584037A NZ58403708A NZ584037A NZ 584037 A NZ584037 A NZ 584037A NZ 584037 A NZ584037 A NZ 584037A NZ 58403708 A NZ58403708 A NZ 58403708A NZ 584037 A NZ584037 A NZ 584037A
Authority
NZ
New Zealand
Prior art keywords
same
formulation containing
dependent kinase
inhibiting compound
treating tumors
Prior art date
Application number
NZ584037A
Other languages
English (en)
Inventor
Valentyn Antochshuk
Rajat Bannerji
Anita Dabbara
David A Parry
Mohammed Shameem
Paul Statkevich
Siu-Long Yao
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NZ584037A publication Critical patent/NZ584037A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ584037A 2007-09-17 2008-09-16 Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same NZ584037A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99418507P 2007-09-17 2007-09-17
US99946907P 2007-10-17 2007-10-17
US5378408P 2008-05-16 2008-05-16
PCT/US2008/010778 WO2009038701A2 (fr) 2007-09-17 2008-09-16 Formulation contenant un composé inhibiteur de la kinase dépendante de la cycline et procédé de traitement de tumeurs l'utilisant

Publications (1)

Publication Number Publication Date
NZ584037A true NZ584037A (en) 2012-08-31

Family

ID=40020243

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ584037A NZ584037A (en) 2007-09-17 2008-09-16 Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same

Country Status (12)

Country Link
EP (1) EP2200584A2 (fr)
JP (1) JP2010539173A (fr)
KR (1) KR20100072253A (fr)
CN (1) CN101854915A (fr)
AU (1) AU2008301925A1 (fr)
BR (1) BRPI0816823A8 (fr)
CA (1) CA2699761A1 (fr)
CO (1) CO6270205A2 (fr)
MX (1) MX2010002927A (fr)
NZ (1) NZ584037A (fr)
SG (1) SG184760A1 (fr)
WO (1) WO2009038701A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012061551A1 (fr) * 2010-11-05 2012-05-10 Millennium Pharmaceuticals, Inc. Administration d'inhibiteur de l'enzyme activatrice de nedd8
TWI632921B (zh) * 2011-10-19 2018-08-21 大塚製藥股份有限公司 口服溶液
MX2016002273A (es) 2013-08-20 2016-05-31 Merck Sharp & Dohme Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
KR20100072253A (ko) 2010-06-30
BRPI0816823A2 (pt) 2015-03-10
SG184760A1 (en) 2012-10-30
MX2010002927A (es) 2010-06-01
WO2009038701A2 (fr) 2009-03-26
BRPI0816823A8 (pt) 2016-02-10
CA2699761A1 (fr) 2009-03-26
CN101854915A (zh) 2010-10-06
EP2200584A2 (fr) 2010-06-30
JP2010539173A (ja) 2010-12-16
AU2008301925A1 (en) 2009-03-26
WO2009038701A3 (fr) 2009-09-11
CO6270205A2 (es) 2011-04-20

Similar Documents

Publication Publication Date Title
NZ597260A (en) Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
MX2009008953A (es) Compuestos como inhibidores de angiogenesis.
MX2009009843A (es) Compuestos espiro sustituidos como inhibidores de la angiogenesis.
MX2007013624A (es) Inhibidores de proteina cinasa.
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
EA201000552A1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
GB0112348D0 (en) Compounds
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
AU2009282962A8 (en) Compounds as kinase inhibitors
TW200833663A (en) Therapeutic agents
HK1127913A1 (en) Method and compositions for treating hematological malignancies
TW200800990A (en) Azaindole inhibitors of aurora kinases
MX2009005413A (es) Formas cristalinas del acido zoledronico.
SI1678166T1 (sl) Inhibitorji proteinske kinaze
UA89123C2 (ru) Производные пиримидина для лечения абнормального роста клеток
TW200637562A (en) Anti-cancer agent containing α-α-α-trifluorothymidine and thymidine phosphorylase inhibitor in combination
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
NZ597237A (en) Sublingual apomorphine
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MX2008013017A (es) Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.
ZA200508862B (en) Process for the preparation of (4-hydroxy-6-oxo-tetrahydropyran-2-yl) acetonitrile and derivatives thereof

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 3024111, MERCK SHARP + DOHME CORP., 126 EAST LINCOLN AVENUE, RAHWAY, NEW JERSEY 07065, US

Effective date: 20130118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 SEP 2015 BY AJ PARK

Effective date: 20130321

LAPS Patent lapsed